• Media
• News Releases
  • By Year
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • 2005
    • 2004
• Media Resources
  • Corporate
  • Central Nervous System Disorders
  • Cancer
  • Pain
• Featured Profiles
  • Healthcare Professionals
  • Programs
  • Products
• On The Record
  • Cephalon Response to JAMA Article “The Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain”
  • Archive
    • Q&A on Settlements Regarding Investigations into Cephalon Business Practices
    • Our Commitment to Appropriate Interactions with Healthcare Professionals
    • Our Position on Tamper-Deterrent Formulation of Extended-Release Opioids
    • Set the Record Straight About ACTIQ®
    • Set the Record Straight About PROVIGIL®

Home > Media > On The Record

On the Record

Cephalon Comments on March 18, 2009 JAMA Article “The Effects of Modafinil on Dopamine and Dopamine Transporters In the Male Human Brain”

Read Cephalon’s response to findings outlined in the article, which are consistent with what we already know about PROVIGIL® (modafinil) Tablets [C-IV] >>

Q&A on Settlements Regarding Investigations into Cephalon Business Practices

Click here for questions and answers related to settlements and other steps Cephalon has taken to ensure we are able to continue to develop the medications patients and physicians have come to count on. >>

Our Commitment to Appropriate Interactions with Healthcare Professionals

PhRMA, the trade organization that represents the pharmaceutical industry in Washington, D.C. recently announced a new code to guide the interactions of the pharmaceutical industry with healthcare professionals. >>

Cephalon Applying Drug Delivery Expertise Toward Development of Tamper-Deterrent Formulation of Extended-Release Opioids

Unfortunately, tampering with extended-release pain medications has become a serious public health concern. For our part, Cephalon is committed to doing all that we can to promote the safe and responsible use these products. >>